Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, ...

The clearance allows human trials for its one-time treatment targeting a genetic eye disease that causes vision loss.

Scientists have discovered a new CRISPR mechanism with precise activity, expanding the potential applications of the existing ...

Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...

Researchers from Würzburg, Braunschweig, and the US identifiy Cas12a3 nuclease showing precise activity. Their study is ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources ...

PHILADELPHIA, January 07, 2026--iECURE Receives FDA Regenerative Medicine Advanced Therapy Designation for ECUR-506 for ...

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

Plant regeneration relies on a delicate balance between stem cell renewal and differentiation, yet the evolutionary origin ...